India's Substitution And 'Similar' Generics Poser
India's Drugs Technical Advisory Board (DTAB) has rejected a proposal to allow chemists to substitute a drug formulation with a same-ingredient generic or a cut-price brand name product, but the decision has unwittingly raised some interesting questions on how the 'pharmacy of the world' should deal with interchangeable and "similar" generics.
You may also be interested in...
India has outlined a set of initiatives to revive its thus far "unsatisfactory" "Jan Aushadhi" cut-price generic medicines scheme, including a distribution effort beyond the exclusive stores for these products and potentially even offering online purchases and home delivery.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.